SOLANA BEACH, Calif., and VERO BEACH, Fla. — November 4, 2025 — Leads & Copy —
QOL Medical, LLC will acquire Evoke Pharma, Inc. (NASDAQ: EVOK) for $11.00 per share in cash, representing a 139.7% premium to the most recent Nasdaq closing price. The transaction, unanimously approved by both companies’ boards, is expected to close by the end of 2025.
The acquisition reflects the strategic value of GIMOTI®, Evoke’s commercial product, which is the first and only FDA-approved nasal spray formulation of metoclopramide for the treatment of acute and recurrent diabetic gastroparesis in adults. The purchase price represents a premium of 139.7% to Evoke’s closing share price on November 3, 2025.
Matt D’Onofrio, Founder and Chief Executive Officer of Evoke, said the transaction recognizes the importance of Evoke’s patient-centered therapy with a growing commercial presence, and that QOL Medical’s strong commercial GI experience, manufacturing capabilities, and commitment to continuity make them an ideal partner.
Derick Cooper, Chief Executive Officer of QOL Medical, said the strategic alignment between QOL and Evoke will strengthen QOL’s GI portfolio and advance their mission to support patients living with rare and underserved gastrointestinal conditions.
Stifel is acting as exclusive financial advisor and Latham & Watkins is serving as legal counsel to Evoke. Hill Ward Henderson is serving as legal counsel to QOL Medical.
Contact:
Daniel Kontoh-Boateng
DKB Partners
Tel: 862-213-1398
dboateng@dkbpartners.net
Chelsea King
QOL Medical, LLC
Tel: 866-469-3773 x1091
cking@qolmed.com
Source: QOL Medical, LLC
